Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nahad Sedaghat
Observed names:
N. Sedaghat,
Sedaghat, Nahad
Institutions:
Isfahan University of Medical Sciences,
Alzahra Medical and Education Center
Observed institutions:
Isfahan University of Medical Sciences,
Kashan University of Medical Sciences,
UNSW Sydney,
Universal Scientific Education and Research Network,
Prince of Wales Hospital,
Alzahra Medical and Education Center,
Shahid Beheshti University of Medical Sciences
show all 7
ORCID:
0000-0002-2796-6791
Observed ORCID:
0000-0002-2796-6791
OpenAlex ID:
A5004125514
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
2021
·
Masoud Etemadifar
, Nahad Sedaghat
, et al.
·
Multiple Sclerosis and Related Disorders
·
58
PDF
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
2022
·
Masoud Etemadifar
, Hosein Nouri
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
47
PDF
Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient
2021
·
Masoud Etemadifar
, Amirhossein Akhavan Sigari
, et al.
·
Human Vaccines & Immunotherapeutics
·
34
PDF
Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis
2021
·
M. Etemadifar
, H. Nouri
, et al.
·
Revue Neurologique
·
33
PDF
Conus medullaris involvement in demyelinating disorders of the CNS: A comparative study
2021
·
Masoud Etemadifar
, Mehri Salari
, et al.
·
Multiple Sclerosis and Related Disorders
·
28
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
2022
·
Masoud Etemadifar
, Amir Parsa Abhari
, et al.
·
BMC Neurology
·
26
PDF
SARS-CoV-2 Serology Among People with Multiple Sclerosis on Disease-Modifying Therapies after BBIBP-CorV (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine
2021
·
Masoud Etemadifar
, Nahad Sedaghat
, et al.
·
Multiple Sclerosis and Related Disorders
·
24
PDF
Re-Evaluating the Effect of Preoperative Tranexamic Acid on Blood Loss and Field Quality During Rhinoplasty: A Randomized Double-Blinded Controlled Trial
2021
·
Sayed Lotfollah Afzali
, Hesam Panahi
, et al.
·
Aesthetic Plastic Surgery
·
23
Movement Disorders Associated with COVID-19
2021
·
Mehri Salari
, Bahareh Zaker Harofteh
, et al.
·
Parkinson s Disease
·
20
PDF
Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
2022
·
Masoud Etemadifar
, Hosein Nouri
, et al.
·
Human Vaccines & Immunotherapeutics
·
16
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
2022
·
Masoud Etemadifar
, Amir Parsa Abhari
, et al.
·
Human Vaccines & Immunotherapeutics
·
16
Inducing chimeric antigen receptor (CAR) regulatory T cells in-vivo: A novel concept for a potential feasible cure of demyelinating diseases
2021
·
Nahad Sedaghat
, Masoud Etemadifar
·
Multiple Sclerosis and Related Disorders
·
15
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors
2022
·
Masoud Etemadifar
, Mehri Salari
, et al.
·
Multiple Sclerosis and Related Disorders
·
14
Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature
2022
·
Masoud Etemadifar
, Amir Reza Mansouri
, et al.
·
Neuroimmunology Reports
·
12
PDF
Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review
2024
·
Masoud Etemadifar
, Hosein Nouri
, et al.
·
Multiple Sclerosis and Related Disorders
·
11
Effect of enteral probiotics on prognostic scores and C-reactive protein levels in critically ill multiple trauma patients: A randomized, double-blind, placebo-controlled clinical trial
2023
·
Saeed Abbasi
, Amirhossein Akhavan Sigari
, et al.
·
Clinical Nutrition ESPEN
·
10
Effect of Disease-Modifying Therapies on Clinical Efficacy of COVID-19 Inactivated Vaccination among People with Multiple Sclerosis
2022
·
Masoud Etemadifar
, Amir Parsa Abhari
, et al.
·
Journal of the Neurological Sciences
·
9
PDF
Anxiolytic Effect of Jasmine Aromatherapy in Pediatric Dental Procedures: A Single-Blinded Randomized Placebo-Controlled Trial
2024
·
Mehdi Jafarzadeh Samani
, Sanaz Ziaei
, et al.
·
Frontiers in Dentistry
·
8
Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis
2022
·
Nahad Sedaghat
, Masoud Etemadifar
·
Multiple Sclerosis and Related Disorders
·
8
Dimethyl Fumarate for Pediatric-Onset Multiple Sclerosis: A Systematic Review
2025
·
Masoud Etemadifar
, Hasan Kaveyee
, et al.
·
Pediatric Neurology
·
6
Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
2022
·
Niloofar Najarzadegan
, Mahboobeh Madani
, et al.
·
PLoS ONE
·
5
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
2021
·
Nahad Sedaghat
·
Multiple Sclerosis and Related Disorders
·
4
PDF
Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
2021
·
Masoud Etemadifar
, Ramin Sami
, et al.
·
Journal of Research in Medical Sciences
·
4
WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
2020
·
M. Etemadifar
, A. Aghababaee
, et al.
·
Revue Neurologique
·
4
PDF
The relative frequency of Myasthenia Gravis in patients with Multiple Sclerosis and Neuromyelitis Optica
2021
·
Masoud Etemadifar
, Amirhossein Akhavan Sigari
, et al.
·
Research Square
·
3
PDF
Show more works
View as search
Works count:
51
Citation count:
455
H-index:
13
I10-index:
16
Year
Topic
Type